ALFA Finder| Metric | Q4 FY26 | Q4 FY25 | |
|---|---|---|---|
| Revenue from operations | 168.7 | — | 151.7 |
| Other income | 10.3 | — | 6.7 |
| Total income | 179.0 | — | 158.4 |
| Profit before exceptional items & tax | 50.5 | — | 43.9 |
| Exceptional items | 4.0 | — | 0.0 |
| Profit before tax | 46.5 | — | 43.9 |
| Net profit | 34.7 | — | 32.1 |
| Operating margin | 26.0% | — | 27.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +8.10% |
|---|---|
| Revenue, year on year | +11.20% |
| Operating profit, year on year | -3.90% |
BSE results filing, NSE: JENBURPH. Figures extracted from the filing.
Jenburkt Pharmaceuticals Ltd: key numbers
- Share price
- ₹963.45
- Market cap
- ₹425.2 Cr
- Revenue (annual)
- ₹168.7 Cr
- Net profit (annual)
- ₹34.74 Cr
- P/E (TTM)
- 12.9×Sector 43.8×
- Promoter holding
- 46.62%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jenburkt Pharmaceuticals Ltd
All →Jenburkt Pharmaceuticals Capital Structure Change
Counter Cyclical Investments Private Limited acquired 4,608 equity shares of Jenburkt Pharmaceuticals Ltd through the open market. This acquisition increased the acquirer's total holding from 5.01% to 5.11%.
Jenburkt Pharmaceuticals Q2 FY27 Results: Net Profit ₹10.2 Cr, Up 0.0% YoY
Jenburkt Pharmaceuticals posted Q2 revenue of Rs. 4,831.82 lakhs and PAT of Rs. 1,020.94 lakhs. Results were approved on 3 November 2026.
- Key figure
- Net profit ₹10.2 Cr · +0.0% YoY
Jenburkt Pharmaceuticals Board Meeting Date
Jenburkt Pharmaceuticals has intimated that its Board will meet on 3 Nov 2026 to consider Q2/H1-26 financial results. No decision has been taken yet.
Jenburkt Pharmaceuticals Capital Structure Change
Counter Cyclical Investments Private Limited acquired 326 shares of Jenburkt Pharmaceuticals Ltd in the open market, increasing its total shareholding from 4.99% to 5.01%.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals submitted a certificate under SEBI Regulation 74(5) regarding share dematerialization for the quarter ended September 30, 2026.
Jenburkt Pharmaceuticals Other Announcement
Jenburkt Pharmaceuticals clarified its shares are permitted to trade on NSE without a listing application. The shares remain listed on BSE under the Permitted to Trade category.